{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":7,"sponsored":0,"items":[{"id":"n_oq5fummcwklcktr6qltq","seq":1153221,"kind":"article","title":"Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69731983-zealand-pharma-announces-opening-of-new-research-hub-in-cambridge-massachusetts-399.htm","published":"2026-10-01T14:35:10Z","seen":"2026-10-01T14:35:10Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","business","politics","health"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"},{"id":"Q49111","name":"Cambridge","type":"place"},{"id":"Q771","name":"Massachusetts","type":"place"}],"story":"st_wwf2oxzanimp2rpn6zoa","category":"economy-business","category_p":0.38,"category2":"health","sentiment":"positive","tone":0.21,"political":0.03},{"id":"n_3wkdjnqiu3ors3zgwlna","seq":1094682,"kind":"article","title":"Zealand Pharma-aktien falder efter nye forsøgsdata","title_en":"Zealand Pharma shares fall after new trial data","url":"https://www.berlingske.dk/business/zealand-pharma-aktien-falder-efter-nye-forsoegsdata?referrer=RSS","summary":"Zealand Pharma-aktien handles 8,5 procent lavere efter nye fase 3-resultater med vægttabsmidlet survodutid.","published":"2026-10-01T08:45:45Z","seen":"2026-10-01T09:01:04Z","lang":"da","country":"DK","source":{"id":"kite-berlingske-dk-a0a3d7","name":"berlingske.dk","domain":"berlingske.dk","outlet":{"wikidata":"Q59055","name":"Berlingske","type":"newspaper","country":"DK","designations":["daily newspaper","newspaper","weekly newspaper"]}},"via":"kite-berlingske-dk-a0a3d7","topics":["business"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"}],"image":"https://akamai-aptoma-production.bmcdn.dk/users/berlingske/images/163178904.webp?accessToken=da4e45007a53dbad7f3e0fe3a7ca6741a6530e9d5fcd52c37e96cdb7d459d564&t[quality]=70&t[strip]=true","story":"st_ntjv2rrwywoc4k4dd7yq","category":"health","category_p":0.46,"category2":"economy-business","sentiment":"negative","tone":-0.79,"political":0.07},{"id":"n_odd5oew2qtpjmn3pkv4a","seq":1089015,"kind":"article","title":"Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69726969-zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvement-399.htm","published":"2026-10-01T08:33:23Z","seen":"2026-10-01T08:33:23Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"},{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.76,"sentiment":"positive","tone":0.03,"political":0.02},{"id":"n_ntjv2rrwywoc4k4dd7yq","seq":1094891,"kind":"article","title":"Zealand Pharma dykker stort efter nye forsøgsdata","title_en":"Zealand Pharma dives into new trial data","url":"https://borsen.dk/nyheder/virksomheder/zealand-pharma-dykker-stort-efter-nye-forsogsdata","summary":"Zealand Pharma er i frit fald torsdag, efter at partneren Boehringer Ingelheim har fremlagt nye data med midlet survodutid fra et fase 3-studie. Aktien står kl. 10.08 til 241,00 kr., hvilket svarer til et kursfald på 11,1 pct.","published":"2026-10-01T07:56:14Z","seen":"2026-10-01T09:07:49Z","lang":"da","country":"DK","source":{"id":"kite-borsen-dk-ead9a0","name":"borsen.dk","domain":"borsen.dk","outlet":{"wikidata":"Q5208470","name":"Dagbladet Børsen","type":"newspaper","country":"DK","designations":["daily newspaper","newspaper"]}},"via":"kite-borsen-dk-ead9a0","entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"}],"image":"https://media.borsen.dk/brapi/size/1200/006d3e97-1f3b-4662-903f-4b8c022db54f-landscape/4098780-20261001081048/9f7275c65046368bea74ee1d8267207e25bd07d9601f199af1d460a0d7c41e5c.jpg","story":"st_ntjv2rrwywoc4k4dd7yq","category":"economy-business","category_p":0.5,"category2":"health","sentiment":"negative","tone":-0.75,"political":0.04},{"id":"n_p3tzxf4zj7upivtww2ka","seq":1079717,"kind":"press_release","title":"Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html","summary":"Company announcement – No. 52 / 2026","published":"2026-10-01T07:30:00Z","seen":"2026-10-01T07:52:04Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","copenhagen:zeal","dk0060257814","7716"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"},{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"mentions":2,"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.77,"sentiment":"positive","tone":0.48,"political":0.02},{"id":"n_kuzdc5yvijted4a6ykyq","seq":780782,"kind":"article","title":"Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology","url":"https://www.manilatimes.net/2026/09/30/tmt-newswire/globenewswire/zealand-pharma-to-present-additional-data-from-phase-2-zupreme-1-trial-for-petrelintide-at-easd-2026-and-announces-publication-of-trial-results-in-the-lancet-diabetes-endocrinology/2435635","published":"2026-09-29T22:10:00Z","seen":"2026-09-29T22:40:41Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"}],"story":"st_lttu7lgs56pzz7vhtuya","category":"health","category_p":0.63,"sentiment":"neutral","tone":-0.1,"political":0.05},{"id":"n_5yqno6g5avolgbhyskca","seq":457737,"kind":"press_release","title":"Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)","url":"https://www.globenewswire.com/news-release/2026/09/28/3370061/0/en/zealand-pharma-transactions-related-to-share-buy-back-program-week-39-2026.html","summary":"Company announcement No. 50 / 2026","published":"2026-09-28T15:00:00Z","seen":"2026-09-28T15:06:27Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","copenhagen:zeal","dk0060257814","7716"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"}],"mentions":2,"story":"st_5yqno6g5avolgbhyskca","category":"economy-business","category_p":0.94,"sentiment":"neutral","tone":0.23,"political":0.04}]}